Rigel Pharmaceuticals, Inc. (RIGL) to Release Earnings on Monday
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) is set to post its quarterly earnings results after the market closes on Monday, October 30th. Analysts expect Rigel Pharmaceuticals to post earnings of ($0.14) per share for the quarter.
Rigel Pharmaceuticals (NASDAQ:RIGL) last posted its earnings results on Tuesday, August 1st. The biotechnology company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.01). Rigel Pharmaceuticals had a negative return on equity of 105.86% and a negative net margin of 354.14%. During the same period in the previous year, the firm posted ($0.15) EPS. On average, analysts expect Rigel Pharmaceuticals to post $-0.6 EPS for the current fiscal year and $-0.55 EPS for the next fiscal year.
Shares of Rigel Pharmaceuticals, Inc. (RIGL) opened at 3.89 on Monday. Rigel Pharmaceuticals, Inc. has a 1-year low of $1.94 and a 1-year high of $4.33. The company’s 50-day moving average price is $3.04 and its 200 day moving average price is $2.71. The stock’s market cap is $483.88 million.
RIGL has been the subject of a number of analyst reports. BMO Capital Markets reissued a “buy” rating and issued a $5.00 price target on shares of Rigel Pharmaceuticals in a report on Monday, October 2nd. Jefferies Group LLC reissued a “buy” rating and issued a $5.00 price target on shares of Rigel Pharmaceuticals in a report on Wednesday, October 4th. Zacks Investment Research raised Rigel Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, September 20th. ValuEngine downgraded Rigel Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Finally, BidaskClub downgraded Rigel Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Friday, July 28th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $6.75.
TRADEMARK VIOLATION WARNING: “Rigel Pharmaceuticals, Inc. (RIGL) to Release Earnings on Monday” was posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another site, it was stolen and reposted in violation of United States and international copyright & trademark law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/23/rigel-pharmaceuticals-inc-rigl-to-release-earnings-on-monday.html.
About Rigel Pharmaceuticals
Rigel Pharmaceuticals, Inc is a clinical-stage biotechnology company. The Company is engaged in the discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s pioneering research focuses on signaling pathways that are critical to disease mechanisms.
Receive News & Ratings for Rigel Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rigel Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.